Development of Effervescent Granules with Solid Dispersion of Furazolidone
Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, prac...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
A. O. Elagina [verfasserIn] A. V. Beliatskaya [verfasserIn] I. I. Krasnyuk (Jr.) [verfasserIn] I. I. Krasnyuk [verfasserIn] O. I. Stepanova [verfasserIn] A. N. Vorob'yov [verfasserIn] T. V. Fateeva [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Разработка и регистрация лекарственных средств - LLC Center of Pharmaceutical Analytics (LLC «CPHA»), 2020, 11(2022), 1, Seite 75-81 |
|---|---|
| Übergeordnetes Werk: |
volume:11 ; year:2022 ; number:1 ; pages:75-81 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.33380/2305-2066-2022-11-1-75-81 |
|---|
| Katalog-ID: |
DOAJ029612861 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ029612861 | ||
| 003 | DE-627 | ||
| 005 | 20230410120318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.33380/2305-2066-2022-11-1-75-81 |2 doi | |
| 035 | |a (DE-627)DOAJ029612861 | ||
| 035 | |a (DE-599)DOAJ3d17243bd1c64a8995fb0ff120267a9a | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a HD9665-9675 | |
| 100 | 0 | |a A. O. Elagina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of Effervescent Granules with Solid Dispersion of Furazolidone |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS > 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production". | ||
| 650 | 4 | |a фуразолидон | |
| 650 | 4 | |a твердые дисперсии | |
| 650 | 4 | |a поливинилпирролидон (пвп) | |
| 650 | 4 | |a шипучие гранулы | |
| 650 | 4 | |a растворимость | |
| 650 | 4 | |a 2 класс бкс | |
| 653 | 0 | |a Pharmaceutical industry | |
| 700 | 0 | |a A. V. Beliatskaya |e verfasserin |4 aut | |
| 700 | 0 | |a I. I. Krasnyuk (Jr.) |e verfasserin |4 aut | |
| 700 | 0 | |a I. I. Krasnyuk |e verfasserin |4 aut | |
| 700 | 0 | |a O. I. Stepanova |e verfasserin |4 aut | |
| 700 | 0 | |a A. N. Vorob'yov |e verfasserin |4 aut | |
| 700 | 0 | |a T. V. Fateeva |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Разработка и регистрация лекарственных средств |d LLC Center of Pharmaceutical Analytics (LLC «CPHA»), 2020 |g 11(2022), 1, Seite 75-81 |w (DE-627)1760622966 |x 26585049 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:1 |g pages:75-81 |
| 856 | 4 | 0 | |u https://doi.org/10.33380/2305-2066-2022-11-1-75-81 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/3d17243bd1c64a8995fb0ff120267a9a |z kostenfrei |
| 856 | 4 | 0 | |u https://www.pharmjournal.ru/jour/article/view/1164 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2305-2066 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-5049 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 1 |h 75-81 | ||
| author_variant |
a o e aoe a v b avb i i k j iikj i i k iik o i s ois a n v anv t v f tvf |
|---|---|
| matchkey_str |
article:26585049:2022----::eeomnoefrecngauewtsldipr |
| hierarchy_sort_str |
2022 |
| callnumber-subject-code |
HD |
| publishDate |
2022 |
| allfields |
10.33380/2305-2066-2022-11-1-75-81 doi (DE-627)DOAJ029612861 (DE-599)DOAJ3d17243bd1c64a8995fb0ff120267a9a DE-627 ger DE-627 rakwb rus HD9665-9675 A. O. Elagina verfasserin aut Development of Effervescent Granules with Solid Dispersion of Furazolidone 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS > 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production". фуразолидон твердые дисперсии поливинилпирролидон (пвп) шипучие гранулы растворимость 2 класс бкс Pharmaceutical industry A. V. Beliatskaya verfasserin aut I. I. Krasnyuk (Jr.) verfasserin aut I. I. Krasnyuk verfasserin aut O. I. Stepanova verfasserin aut A. N. Vorob'yov verfasserin aut T. V. Fateeva verfasserin aut In Разработка и регистрация лекарственных средств LLC Center of Pharmaceutical Analytics (LLC «CPHA»), 2020 11(2022), 1, Seite 75-81 (DE-627)1760622966 26585049 nnns volume:11 year:2022 number:1 pages:75-81 https://doi.org/10.33380/2305-2066-2022-11-1-75-81 kostenfrei https://doaj.org/article/3d17243bd1c64a8995fb0ff120267a9a kostenfrei https://www.pharmjournal.ru/jour/article/view/1164 kostenfrei https://doaj.org/toc/2305-2066 Journal toc kostenfrei https://doaj.org/toc/2658-5049 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 11 2022 1 75-81 |
| spelling |
10.33380/2305-2066-2022-11-1-75-81 doi (DE-627)DOAJ029612861 (DE-599)DOAJ3d17243bd1c64a8995fb0ff120267a9a DE-627 ger DE-627 rakwb rus HD9665-9675 A. O. Elagina verfasserin aut Development of Effervescent Granules with Solid Dispersion of Furazolidone 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS > 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production". фуразолидон твердые дисперсии поливинилпирролидон (пвп) шипучие гранулы растворимость 2 класс бкс Pharmaceutical industry A. V. Beliatskaya verfasserin aut I. I. Krasnyuk (Jr.) verfasserin aut I. I. Krasnyuk verfasserin aut O. I. Stepanova verfasserin aut A. N. Vorob'yov verfasserin aut T. V. Fateeva verfasserin aut In Разработка и регистрация лекарственных средств LLC Center of Pharmaceutical Analytics (LLC «CPHA»), 2020 11(2022), 1, Seite 75-81 (DE-627)1760622966 26585049 nnns volume:11 year:2022 number:1 pages:75-81 https://doi.org/10.33380/2305-2066-2022-11-1-75-81 kostenfrei https://doaj.org/article/3d17243bd1c64a8995fb0ff120267a9a kostenfrei https://www.pharmjournal.ru/jour/article/view/1164 kostenfrei https://doaj.org/toc/2305-2066 Journal toc kostenfrei https://doaj.org/toc/2658-5049 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 11 2022 1 75-81 |
| allfields_unstemmed |
10.33380/2305-2066-2022-11-1-75-81 doi (DE-627)DOAJ029612861 (DE-599)DOAJ3d17243bd1c64a8995fb0ff120267a9a DE-627 ger DE-627 rakwb rus HD9665-9675 A. O. Elagina verfasserin aut Development of Effervescent Granules with Solid Dispersion of Furazolidone 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS > 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production". фуразолидон твердые дисперсии поливинилпирролидон (пвп) шипучие гранулы растворимость 2 класс бкс Pharmaceutical industry A. V. Beliatskaya verfasserin aut I. I. Krasnyuk (Jr.) verfasserin aut I. I. Krasnyuk verfasserin aut O. I. Stepanova verfasserin aut A. N. Vorob'yov verfasserin aut T. V. Fateeva verfasserin aut In Разработка и регистрация лекарственных средств LLC Center of Pharmaceutical Analytics (LLC «CPHA»), 2020 11(2022), 1, Seite 75-81 (DE-627)1760622966 26585049 nnns volume:11 year:2022 number:1 pages:75-81 https://doi.org/10.33380/2305-2066-2022-11-1-75-81 kostenfrei https://doaj.org/article/3d17243bd1c64a8995fb0ff120267a9a kostenfrei https://www.pharmjournal.ru/jour/article/view/1164 kostenfrei https://doaj.org/toc/2305-2066 Journal toc kostenfrei https://doaj.org/toc/2658-5049 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 11 2022 1 75-81 |
| allfieldsGer |
10.33380/2305-2066-2022-11-1-75-81 doi (DE-627)DOAJ029612861 (DE-599)DOAJ3d17243bd1c64a8995fb0ff120267a9a DE-627 ger DE-627 rakwb rus HD9665-9675 A. O. Elagina verfasserin aut Development of Effervescent Granules with Solid Dispersion of Furazolidone 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS > 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production". фуразолидон твердые дисперсии поливинилпирролидон (пвп) шипучие гранулы растворимость 2 класс бкс Pharmaceutical industry A. V. Beliatskaya verfasserin aut I. I. Krasnyuk (Jr.) verfasserin aut I. I. Krasnyuk verfasserin aut O. I. Stepanova verfasserin aut A. N. Vorob'yov verfasserin aut T. V. Fateeva verfasserin aut In Разработка и регистрация лекарственных средств LLC Center of Pharmaceutical Analytics (LLC «CPHA»), 2020 11(2022), 1, Seite 75-81 (DE-627)1760622966 26585049 nnns volume:11 year:2022 number:1 pages:75-81 https://doi.org/10.33380/2305-2066-2022-11-1-75-81 kostenfrei https://doaj.org/article/3d17243bd1c64a8995fb0ff120267a9a kostenfrei https://www.pharmjournal.ru/jour/article/view/1164 kostenfrei https://doaj.org/toc/2305-2066 Journal toc kostenfrei https://doaj.org/toc/2658-5049 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 11 2022 1 75-81 |
| allfieldsSound |
10.33380/2305-2066-2022-11-1-75-81 doi (DE-627)DOAJ029612861 (DE-599)DOAJ3d17243bd1c64a8995fb0ff120267a9a DE-627 ger DE-627 rakwb rus HD9665-9675 A. O. Elagina verfasserin aut Development of Effervescent Granules with Solid Dispersion of Furazolidone 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS > 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production". фуразолидон твердые дисперсии поливинилпирролидон (пвп) шипучие гранулы растворимость 2 класс бкс Pharmaceutical industry A. V. Beliatskaya verfasserin aut I. I. Krasnyuk (Jr.) verfasserin aut I. I. Krasnyuk verfasserin aut O. I. Stepanova verfasserin aut A. N. Vorob'yov verfasserin aut T. V. Fateeva verfasserin aut In Разработка и регистрация лекарственных средств LLC Center of Pharmaceutical Analytics (LLC «CPHA»), 2020 11(2022), 1, Seite 75-81 (DE-627)1760622966 26585049 nnns volume:11 year:2022 number:1 pages:75-81 https://doi.org/10.33380/2305-2066-2022-11-1-75-81 kostenfrei https://doaj.org/article/3d17243bd1c64a8995fb0ff120267a9a kostenfrei https://www.pharmjournal.ru/jour/article/view/1164 kostenfrei https://doaj.org/toc/2305-2066 Journal toc kostenfrei https://doaj.org/toc/2658-5049 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 11 2022 1 75-81 |
| language |
Russian |
| source |
In Разработка и регистрация лекарственных средств 11(2022), 1, Seite 75-81 volume:11 year:2022 number:1 pages:75-81 |
| sourceStr |
In Разработка и регистрация лекарственных средств 11(2022), 1, Seite 75-81 volume:11 year:2022 number:1 pages:75-81 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
фуразолидон твердые дисперсии поливинилпирролидон (пвп) шипучие гранулы растворимость 2 класс бкс Pharmaceutical industry |
| isfreeaccess_bool |
true |
| container_title |
Разработка и регистрация лекарственных средств |
| authorswithroles_txt_mv |
A. O. Elagina @@aut@@ A. V. Beliatskaya @@aut@@ I. I. Krasnyuk (Jr.) @@aut@@ I. I. Krasnyuk @@aut@@ O. I. Stepanova @@aut@@ A. N. Vorob'yov @@aut@@ T. V. Fateeva @@aut@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
1760622966 |
| id |
DOAJ029612861 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ029612861</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410120318.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.33380/2305-2066-2022-11-1-75-81</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ029612861</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3d17243bd1c64a8995fb0ff120267a9a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HD9665-9675</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. O. Elagina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development of Effervescent Granules with Solid Dispersion of Furazolidone</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS &gt; 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production".</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фуразолидон</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">твердые дисперсии</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">поливинилпирролидон (пвп)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">шипучие гранулы</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">растворимость</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">2 класс бкс</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Beliatskaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. I. Krasnyuk (Jr.)</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. I. Krasnyuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O. I. Stepanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. N. Vorob'yov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. V. Fateeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Разработка и регистрация лекарственных средств</subfield><subfield code="d">LLC Center of Pharmaceutical Analytics (LLC «CPHA»), 2020</subfield><subfield code="g">11(2022), 1, Seite 75-81</subfield><subfield code="w">(DE-627)1760622966</subfield><subfield code="x">26585049</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:75-81</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.33380/2305-2066-2022-11-1-75-81</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3d17243bd1c64a8995fb0ff120267a9a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.pharmjournal.ru/jour/article/view/1164</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2305-2066</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2658-5049</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">75-81</subfield></datafield></record></collection>
|
| callnumber-first |
H - Social Science |
| author |
A. O. Elagina |
| spellingShingle |
A. O. Elagina misc HD9665-9675 misc фуразолидон misc твердые дисперсии misc поливинилпирролидон (пвп) misc шипучие гранулы misc растворимость misc 2 класс бкс misc Pharmaceutical industry Development of Effervescent Granules with Solid Dispersion of Furazolidone |
| authorStr |
A. O. Elagina |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760622966 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
HD9665-9675 |
| illustrated |
Not Illustrated |
| issn |
26585049 |
| topic_title |
HD9665-9675 Development of Effervescent Granules with Solid Dispersion of Furazolidone фуразолидон твердые дисперсии поливинилпирролидон (пвп) шипучие гранулы растворимость 2 класс бкс |
| topic |
misc HD9665-9675 misc фуразолидон misc твердые дисперсии misc поливинилпирролидон (пвп) misc шипучие гранулы misc растворимость misc 2 класс бкс misc Pharmaceutical industry |
| topic_unstemmed |
misc HD9665-9675 misc фуразолидон misc твердые дисперсии misc поливинилпирролидон (пвп) misc шипучие гранулы misc растворимость misc 2 класс бкс misc Pharmaceutical industry |
| topic_browse |
misc HD9665-9675 misc фуразолидон misc твердые дисперсии misc поливинилпирролидон (пвп) misc шипучие гранулы misc растворимость misc 2 класс бкс misc Pharmaceutical industry |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Разработка и регистрация лекарственных средств |
| hierarchy_parent_id |
1760622966 |
| hierarchy_top_title |
Разработка и регистрация лекарственных средств |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760622966 |
| title |
Development of Effervescent Granules with Solid Dispersion of Furazolidone |
| ctrlnum |
(DE-627)DOAJ029612861 (DE-599)DOAJ3d17243bd1c64a8995fb0ff120267a9a |
| title_full |
Development of Effervescent Granules with Solid Dispersion of Furazolidone |
| author_sort |
A. O. Elagina |
| journal |
Разработка и регистрация лекарственных средств |
| journalStr |
Разработка и регистрация лекарственных средств |
| callnumber-first-code |
H |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
75 |
| author_browse |
A. O. Elagina A. V. Beliatskaya I. I. Krasnyuk (Jr.) I. I. Krasnyuk O. I. Stepanova A. N. Vorob'yov T. V. Fateeva |
| container_volume |
11 |
| class |
HD9665-9675 |
| format_se |
Elektronische Aufsätze |
| author-letter |
A. O. Elagina |
| doi_str_mv |
10.33380/2305-2066-2022-11-1-75-81 |
| author2-role |
verfasserin |
| title_sort |
development of effervescent granules with solid dispersion of furazolidone |
| callnumber |
HD9665-9675 |
| title_auth |
Development of Effervescent Granules with Solid Dispersion of Furazolidone |
| abstract |
Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS > 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production". |
| abstractGer |
Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS > 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production". |
| abstract_unstemmed |
Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS > 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production". |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
1 |
| title_short |
Development of Effervescent Granules with Solid Dispersion of Furazolidone |
| url |
https://doi.org/10.33380/2305-2066-2022-11-1-75-81 https://doaj.org/article/3d17243bd1c64a8995fb0ff120267a9a https://www.pharmjournal.ru/jour/article/view/1164 https://doaj.org/toc/2305-2066 https://doaj.org/toc/2658-5049 |
| remote_bool |
true |
| author2 |
A. V. Beliatskaya I. I. Krasnyuk (Jr.) I. I. Krasnyuk O. I. Stepanova A. N. Vorob'yov T. V. Fateeva |
| author2Str |
A. V. Beliatskaya I. I. Krasnyuk (Jr.) I. I. Krasnyuk O. I. Stepanova A. N. Vorob'yov T. V. Fateeva |
| ppnlink |
1760622966 |
| callnumber-subject |
HD - Industries, Land Use, Labor |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.33380/2305-2066-2022-11-1-75-81 |
| callnumber-a |
HD9665-9675 |
| up_date |
2024-07-03T23:39:57.322Z |
| _version_ |
1803603145996107776 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ029612861</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410120318.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.33380/2305-2066-2022-11-1-75-81</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ029612861</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3d17243bd1c64a8995fb0ff120267a9a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HD9665-9675</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. O. Elagina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development of Effervescent Granules with Solid Dispersion of Furazolidone</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction. Treatment of infectious and inflammatory diseases demands active substances (AS), characterized by low resistance of microorganisms, high specificity of the mechanism of action and a wide range of antimicrobial activity. Though furazolidone (FZ) – AS meets these criteria, however, practically insolubility in water significantly limits its use. Use of the solid dispersion method (SD) could increase the solubility and dissolution rate of AS with low water solubility. revious studies indicate an increase in the solubility and dissolution rate of FZ in water from SD with polyvinylpyrrolidone-24 000 (PVP-24 000) in a ratio with AS &gt; 6 : 1 by weight. As a result, it becomes possible to introduce SD FZ into the composition of rapidly dissolving effervescent dosage forms, for example, granules for obtaining solutions for external use for the treatment of infectious and inflammatory diseases.Aim. Development of the composition and technology for producing effervescent granules based on solid dispersions of FZ for obtaining a solution for external use.Materials and methods. FZ substance, polyvinylpyrrolidone-24 000 ± 2000 (PVP-24 000 ± 2000), tartaric acid, malic acid, sodium carbonate anhydrous, ethyl alcohol 96 %, purified water. We provided the granules through fluidized bed granulation. The analysis of the obtained granules included the following parameters: description, granule size, loss in mass on drying, disintegration, uniformity of dosage according to GPМ 1.4.1.0004.15 "Granules". Then followed a qualitative and quantitative determination of AS and analysis of the pH of the aqueous solution of the granules. To study the stability and shelf life of the samples of granules, we laid them to the storage in accordance with GPМ 1.10009.15 "Stability and shelf life of drugs".Results and discussion. We developed he composition and technology of FZ effervescent granules for obtaining a solution for external use. Granules are obtained by separate granulation of the main (containing a SD AS) and acid components, followed by mixing in ratios that provide a solution of FZ with a concentration of 0.004 % in water at room temperature. Later we assessed the quality of the obtained compositions and determined, the shelf life (2 years) and storage conditions (in a dry, dark place at a temperature of 25 °C) of the developed compositions of granules.Conclusion. As a result of technological and chemical-pharmaceutical research using the SD method, we developed a new FZ dosage form – effervescent granules, which makes it possible to obtain an aqueous solution with a concentration of FZ 0.004 % in less than 5 minutes without heating. Based on the results of the work, an application was filed with Rospatent No. 2021105988 dated 10.03.2021, "Fast-dissolving dosage form of furazolidone and a method for its production".</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фуразолидон</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">твердые дисперсии</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">поливинилпирролидон (пвп)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">шипучие гранулы</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">растворимость</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">2 класс бкс</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. V. Beliatskaya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. I. Krasnyuk (Jr.)</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. I. Krasnyuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O. I. Stepanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. N. Vorob'yov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. V. Fateeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Разработка и регистрация лекарственных средств</subfield><subfield code="d">LLC Center of Pharmaceutical Analytics (LLC «CPHA»), 2020</subfield><subfield code="g">11(2022), 1, Seite 75-81</subfield><subfield code="w">(DE-627)1760622966</subfield><subfield code="x">26585049</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:75-81</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.33380/2305-2066-2022-11-1-75-81</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3d17243bd1c64a8995fb0ff120267a9a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.pharmjournal.ru/jour/article/view/1164</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2305-2066</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2658-5049</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">75-81</subfield></datafield></record></collection>
|
| score |
7.401886 |